For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Genta Incorporated

USPTO Granted Patents = 31

% Expired Patents = 22.6

Forward Citations = 667

Loading Chart...

Loading Chart...

37 inventors (with patents filed for the assignee):

David Aaron Schwartz (10 out of 47 patents)

Mark A Reynolds (9 out of 29 patents)

Lyle J Arnold, Jr (9 out of 26 patents)

4. Timothy A Riley (7 out of 43 patents)

5. Robert E Klem (6 out of 8 patents)

6. Brian Patrick Dwyer (5 out of 15 patents)

7. Bob Dale Brown (5 out of 96 patents)

8. William J Daily (5 out of 7 patents)

9. Morteza M Vaghefi (4 out of 5 patents)

10. Thomas N Julian (3 out of 9 patents)

11. Kumar Srinivasan (3 out of 5 patents)

12. Richard I Hogrefe (2 out of 18 patents)

13. Raymond P Warrell, Jr (2 out of 31 patents)

14. Cristina Giachetti (2 out of 6 patents)

15. Raymond P Warrell (1 out of 1 patent)

Core Competencies:

BCL-2 Antisense Oligomers

Pharmaceutical Gallium Compositions

Inhibitory Oligonucleotides

Amide-Based Cationic Lipids

Chimeric Oligonucleoside Compounds

Synthetic Oligomers

Oligonucleotide Analogues

Organophosphorus Synthesis

Antisense Oligonucleotides

RNA Translation Inhibition

Oligonucleotide Cleavage Compounds

Skin Care Package

31 patents: Sort by Forward Citations

1. 7855183 - Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers (2010-12-21),

2. 7842724 - Pharmaceutical gallium compositions and methods (2010-11-30),

3. 7795232 - Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers (2010-09-14),

4. 7456215 - Pharmaceutical gallium compositions and methods (2008-11-25),

5. 7354952 - Pharmaceutical gallium compositions and methods (2008-04-08),

6. 7256284 - Inhibitory oligonucleotides targeted to Bcl-2 (2007-08-14),

7. 7119217 - Tri(alkylcarboxylato)gallium (III) products and pharmaceutical compositions containing them (2006-10-10),

8. 7060690 - Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof (2006-06-13),

9. 6638529 - Amide-based cationic lipids (2003-10-28),

10. 6262036 - Method for inhibiting RNA translation using chimeric oligonucleoside compounds (2001-07-17),

11. 6060456 - Chimeric oligonucleoside compounds (2000-05-09),

12. 6028188 - Synthetic oligomers having chirally pure phosphonate internucleosidyl (2000-02-22),

13. 6020526 - Amide-based cationic lipids (2000-02-01),

14. 6005094 - Oligonucleotide analogues having improved stability at acid pH (1999-12-21),

15. 5986083 - Synthetic oligomers having phosphonate internucleosidyl linkages of (1999-11-16),

Genta Incorporated is a biotechnology company based in San Diego, California, specializing in the development of innovative therapies for cancer and other serious diseases. The company focuses on advancing its proprietary drug candidates through clinical trials, leveraging its expertise in molecular biology and pharmacology. Genta aims to address unmet medical needs by harnessing cutting-edge research and technology, positioning itself as a key player in the biopharmaceutical landscape.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

31 Patents

#206 in San Diego, CA

#2,611 in California

#10,921 in US

#21,238 in the World

San Diego, CA, United States of America

Genta Incorporated

Forward Citations = 667

37 inventors:

David Aaron Schwartz (10 out of 47 patents)

Mark A Reynolds (9 out of 29 patents)

Lyle J Arnold, Jr (9 out of 26 patents)

4. Timothy A Riley (7 out of 43 patents)

5. Robert E Klem (6 out of 8 patents)

Please report any incorrect information to [email protected]

Loading…